Covidien agreed to acquire Somanetics for $25 a share in cash, or $250 million.
twocents@thestreet.com (Andrea Tse), The Street
Wed, 06/16/2010 - 4:32am
Covidien agreed to acquire Somanetics for $25 a share in cash, or $250 million.